![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/10/20/2538895/0/en/Summit-Therapeutics-Presents-Ri-CoDIFy-Trial-Results-for-Microbiome-Sparing-Ridinilazole-at-IDWeek-2022.html
https://www.globenewswire.com/news-release/2022/10/13/2533796/0/en/Summit-Therapeutics-to-Present-Ri-CoDIFy-Trial-Results-for-Microbiome-Sparing-Ridinilazole-at-IDWeek-2022.html
https://www.globenewswire.com/news-release/2022/07/14/2479712/0/en/Summit-Therapeutics-Provides-Update-on-Ridinilazole.html
https://www.fiercebiotech.com/biotech/summit-will-take-scenic-route-fda-mountain-after-c-diff-convo-regulator
https://www.fiercebiotech.com/biotech/summit-carves-out-path-forward-after-c-diff-failure-remains-committed-lead-asset
https://endpts.com/billionaire-bob-duggans-new-antibiotic-play-fails-a-phase-iii-trial-and-investors-arent-happy/
https://globenewswire.com/news-release/2019/02/13/1724505/0/en/Summit-Doses-First-Patient-in-Phase-3-Clinical-Trials-of-Precision-Antibiotic-Ridinilazole-for-C-Difficile-Infection.html
https://globenewswire.com/news-release/2018/09/26/1576319/0/en/Summit-to-Highlight-Potential-of-Precision-Antibiotic-Ridinilazole-to-Treat-C-difficile-Infection-and-Reduce-Recurrent-Disease-at-ID-Week-2018.html